Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
The available evidence consists primarily of animal studies and limited early-phase human trials, with no published phase III clinical trial data demonstrating efficacy in inflammatory bowel disease (IBD).[1][2] The literature describes BPC-157 as a stable gastric pentadecapeptide that was tested in phase II clinical trials for inflammatory bowel disease (referenced as PL 14736), with reports indicating it was "safe" and had "no side effects." However, a 2025 review emphasizes that BPC-157 "has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans."[1][3][2] The preclinical evidence is extensive but limited to animal models
They can also make sure that the level of dosage, frequency of use, and delivery of the medication, render optimal results with minimized side effects
It is non-hormonal and non-stimulant, so it integrates well with other wellness routines
FDA identified potential immunogenicity concerns involving aggregation and peptide-related impurities
US$ 28.19
US$ 21.64
US$ 25.40
US$ 20.57
US$ 20.77